{"name":"Agios Pharmaceuticals, Inc.","slug":"agios-pharmaceuticals-inc","ticker":"","exchange":"","domain":"agios.com","description":"","hq":"Cambridge","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":30013000,"revenueGrowth":97.5,"grossMargin":0,"rdSpend":339535000,"netIncome":-412781000,"cash":1297225000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"AG-181","genericName":"AG-181","slug":"ag-181","indication":"Other","status":"phase_1"},{"name":"AG881 Formulation 1","genericName":"AG881 Formulation 1","slug":"ag881-formulation-1","indication":"Other","status":"phase_1"},{"name":"AG-236","genericName":"AG-236","slug":"ag-236","indication":"Other","status":"phase_1"},{"name":"AG-348 Sequence A","genericName":"AG-348 Sequence A","slug":"ag-348-sequence-a","indication":"Other","status":"phase_1"},{"name":"AG-348 Sequence B","genericName":"AG-348 Sequence B","slug":"ag-348-sequence-b","indication":"Other","status":"phase_1"},{"name":"AG-946","genericName":"AG-946","slug":"ag-946","indication":"Other","status":"phase_1"},{"name":"AG881 Formulation 2","genericName":"AG881 Formulation 2","slug":"ag881-formulation-2","indication":"Other","status":"phase_1"},{"name":"[13C6]AG-348","genericName":"[13C6]AG-348","slug":"13c6-ag-348","indication":"Other","status":"phase_1"},{"name":"[14C]-AG-120","genericName":"[14C]-AG-120","slug":"14c-ag-120","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"AG120","genericName":"AG120","slug":"ag120","indication":"Acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation","status":"phase_1"},{"name":"AG-881","genericName":"AG-881","slug":"ag-881","indication":"Acute myeloid leukemia (AML)","status":"phase_1"},{"name":"AG221","genericName":"AG221","slug":"ag221","indication":"Acute myeloid leukemia","status":"phase_1"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"AG-348","genericName":"AG-348","slug":"ag-348","indication":"Pyruvate kinase deficiency","status":"phase_3"},{"name":"Placebo Matching Mitapivat","genericName":"Placebo Matching Mitapivat","slug":"placebo-matching-mitapivat","indication":"Pyruvate kinase deficiency","status":"phase_3"}]}],"pipeline":[{"name":"AG-181","genericName":"AG-181","slug":"ag-181","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG120","genericName":"AG120","slug":"ag120","phase":"phase_1","mechanism":"Inhibits mutant IDH1 enzyme","indications":["Acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation"],"catalyst":""},{"name":"AG881 Formulation 1","genericName":"AG881 Formulation 1","slug":"ag881-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-236","genericName":"AG-236","slug":"ag-236","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-348","genericName":"AG-348","slug":"ag-348","phase":"phase_3","mechanism":"AG-348 activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and reduce hemolysis.","indications":["Pyruvate kinase deficiency","Sickle cell disease"],"catalyst":""},{"name":"AG-348 Sequence A","genericName":"AG-348 Sequence A","slug":"ag-348-sequence-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-348 Sequence B","genericName":"AG-348 Sequence B","slug":"ag-348-sequence-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-881","genericName":"AG-881","slug":"ag-881","phase":"phase_1","mechanism":"Tet methylcytosine dioxygenase 2 (TET2) inhibitor","indications":["Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"AG-946","genericName":"AG-946","slug":"ag-946","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG221","genericName":"AG221","slug":"ag221","phase":"phase_1","mechanism":"IDH2 inhibitor","indications":["Acute myeloid leukemia"],"catalyst":""},{"name":"AG881 Formulation 2","genericName":"AG881 Formulation 2","slug":"ag881-formulation-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo Matching Mitapivat","genericName":"Placebo Matching Mitapivat","slug":"placebo-matching-mitapivat","phase":"phase_3","mechanism":"Mitapivat activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and function.","indications":["Pyruvate kinase deficiency","Sickle cell disease"],"catalyst":""},{"name":"[13C6]AG-348","genericName":"[13C6]AG-348","slug":"13c6-ag-348","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-AG-120","genericName":"[14C]-AG-120","slug":"14c-ag-120","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNSGtMS2pJT3VRelY3Qm9MM0o3WmNRdVhMNnppalpuQm12bmRmX2tjajlBNHNGbHNXcTdFZ1NNLW1xWXExQ0w1UkRSYjZkSTdwNS10Y2xqNmVhNkMxbGEwdnAxN2RYYi1pVjJ6WUFPa2FGZkw1X0M1dDVIZEZJcFFFdmpUbm1YSHNMLVllaFF5V1kzU2o0V0xLZTZNb1NrYk9B?oc=5","date":"2026-03-31","type":"regulatory","source":"Investor's Business Daily","summary":"The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily","headline":"The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNaUhTYzFqWDRWTGw3Wkl2cVFlOXhoSkZWNkt5Vi1qTWdyYVB6a2dkSWttOVgzbVI1MEJ6UWRZb2pZMk96bDJJbkdXR0o5SzFfcTNUS1VpX2U2QnpvOWxuOHRhNzdCSjBfRFdXSFh2OHRiQWJ2VEdPNVNJNWQ4WS01RGpMOXY5S3hYWjl3akczc05JUFVGQlkybGNyaUJHTXAtSmFvOEVpNEJmdkR5RHpoVG1tQzI1ZUdjUEFVdUstcw?oc=5","date":"2026-03-31","type":"pipeline","source":"Investing.com","summary":"BofA raises Agios Pharma stock price target on SCD filing path - Investing.com","headline":"BofA raises Agios Pharma stock price target on SCD filing path","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOci1TRlVXa0RvbEpfbkVKVW5sVFViUk1XX0RCcTVnZjBFcDdNcjMzZzVZWHlhdkItTF85bkxyWFp5emlUM2pLQU1wdHl6Q2Z3akpBOGM2UWxQZ21wZGlfLXJlc1FLX01mOTY2UVZnLTljLTRrZThjM2hxRDBoeWR2SzROZ09sUmdvR2JPa2ZKWVhIandQVHJLLVlJVUMteUUyejNhTlNESHgtY3czRzMzUjFXbWJQUUxZc3ZhTEQ4N0sybEFNNEVlNGs2ZGdQWWVVRk1aTEM5M0huaDRta3RzVXdR?oc=5","date":"2025-12-24","type":"regulatory","source":"Reuters","summary":"Agios Pharma shares jump as US FDA expands approval for blood disorder drug - Reuters","headline":"Agios Pharma shares jump as US FDA expands approval for blood disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBUb0o0QWdzQ0VsSmNma0V0OFlOaHZ6dmt1eDI5MGtYWTBabUluMTYxRU1sUzVsR28zQjdDcU03ai04ZzFUMExTajFhd3cxV2NqUDlSVGVSdjl4Z19kQnFRSG9WQTliSjJsOVlFQ040V25aVUJvLUFwbjg1SHA2Zw?oc=5","date":"2025-12-24","type":"regulatory","source":"Yahoo Finance","summary":"Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Yahoo Finance","headline":"Agios Pharma shares jump as US FDA expands approval for its blood disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOaG40SE1KOVpoMXZSeE82azg0bkxJTy1DSjliUm5YOHRNYUVBQ3JYZUFGXy1BT0xMaDNyenFoajhhbXZHSENOYWM3MUk4Vjh5WTl2dTY1R2ozbHVsZFhDVHJZQXFIdTlsTUllMHJabXVPVC1kTEVSSVhpWUdGOWJpZmhidlc3VWs0WUdGM2NnZGl1ZFQx?oc=5","date":"2025-12-24","type":"regulatory","source":"Seeking Alpha","summary":"Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha","headline":"Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1TZnptcFNCSWRHNTRZMTBGZ2w1a1NfNERSbl84c29UbXBZQWt0Mlp5UTdaOUJaVE50OFVkLVo4QWZya3ZhUmo4c2k4N0ZqaTNKQlZvNXlIZTJVcjZu?oc=5","date":"2025-12-07","type":"pipeline","source":"Finimize","summary":"Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom - Finimize","headline":"Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQZmIyNkszV1JQTVlhV2FZSEZSNGFpNzVEM2pXUkRwSjZOcjYwS2htX2x3YjdDcDAxQkhCRnR2Qnh6NEpPSVpXX0lwZ2xjMHJKcVBCNVJtUVJ6ajc5ODIzZjdGdWc5dDh6SDlESmU1Q3oxbHdnamRBbDZ4YnJDb1pvdjI5ZzBtREF3MkpTYk9DV2ljUDlqTzlraUQ2a0h2RlRwaVdvYVR3MkNJWHpqNU1Ed2pyeDFiZDlVVlM5dmFlVXdqVXpyWWJR?oc=5","date":"2025-11-25","type":"pipeline","source":"Investing.com","summary":"Cantor Fitzgerald reiterates Overweight rating on Agios Pharma stock - Investing.com","headline":"Cantor Fitzgerald reiterates Overweight rating on Agios Pharma stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQVlhIWHl6eV8yRkVFUG13X2d4aWUtdlV4d1RKUVVGMGs2MXZXZjQyYWQxem85YnZUcFpveWlrVS1ERVhSUmJ3ZHNCSUlScW4yN2lYNWRTSW9ka0JHUzRnZkU0SXJjN2FrMXVITzVQaGwzWHFSeEJzYXVsRC1aOXcxcTMtQmZVcElFdU52TjA5R3NhUG1jNTVUSUl3ajA3TVR4NUR0RkdaWG5Ea1RVeEI3UFpTUXdhMjBDSlRTVFVn?oc=5","date":"2025-11-19","type":"regulatory","source":"Seeking Alpha","summary":"Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility - Seeking Alpha","headline":"Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZ3VlZnRKOE1lbDVkYzVzd0R3NXNQR3U0bGdpMkV5aHdiTHRsT3hBTVJsdTNzdEFud2RpbUQtQ2x3bzJDMWJhYlY4YTNvM2hZaFFrdGhTVWtIT0RXY1pXYk5oaWh4YVBwWVVYcjludlliczlNZjh2R0FFcFg1WjBMdjFFTjk0eUpxSlExVEI4SGFkNGZDWjJ1dkxUU1BqRmdTTjZfQWJuckRCTThMX0l1YkVHRQ?oc=5","date":"2025-09-08","type":"regulatory","source":"Seeking Alpha","summary":"Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive (NASDAQ:AGIO) - Seeking Alpha","headline":"Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive (NASDAQ:AGIO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQMXlIRllYMGVEYWI0M1lGNFg4empoaTltdlJMOUMyc2pfVzRDbGRGdjI1Z1I1bndqZkFaclVyT29EWDljaGIxMjBVcGlTUm9rck51Yi1KY01UN3NiQ0VsYU4taExFYXBiTUVJRnFBWkRGWjVSZ0UxbGZMUjBqVG1fVFF5ZlI1TjRONG01TWhQMmVLU0VGYjVpbXBtcC0?oc=5","date":"2025-09-07","type":"regulatory","source":"RTTNews","summary":"Biotech Stocks Facing FDA Decision In September 2025 - RTTNews","headline":"Biotech Stocks Facing FDA Decision In September 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNeXFWZFdqNTgyemoxVEl2WXhjdk15b3BybnlsbjdlX0lRbzl4d2hRZHFMM0x2M0h0cjBkMlZqLVZqam4tSzh1dUFWMTBCblVwdnhDVkZ3UFZzZ19VQm1WN3p1SU9QbVdBN05SZ0JuQmt5cXZjSC1VOENKcVJwZVBrcHJyMjNvTG5Z?oc=5","date":"2025-08-05","type":"regulatory","source":"Yahoo Finance","summary":"SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance","headline":"SFDA approves Agios Pharma’s Pyrukynd for thalassemia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRmpTSC1Sc0NidUFOcUdGRUtZRUNqRFBjR3lkNE9XV2NFRFdvRDVSMkpWbEs0R0EybHdTdEdJRXJNVllWMkFFazd6Z1A3d1FILWxNYWRXVE9YS240VExtSnNpRUFmRmQ5SnVZN01TRnZjWW1CY2huV3I0cXRKUnRzeXdyRDZiblN5dV95bzRRZjJWdWs2amo2MG5wZ25BOGRTS2x6amduZTdvQQ?oc=5","date":"2024-05-28","type":"deal","source":"BioPharma Dive","summary":"Agios cashes in on cancer drug again with $905M Royalty Pharma deal - BioPharma Dive","headline":"Agios cashes in on cancer drug again with $905M Royalty Pharma deal","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_1":12,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":30013000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":30013000,"period":"2018-12-31"},{"value":15198000,"period":"2018-09-30"},{"value":40414000,"period":"2018-06-30"},{"value":8762000,"period":"2018-03-31"},{"value":43011000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":339535000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-412781000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1297225000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}